Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
The study is intended to demonstrate that macitentan does not have an effect on cardiac
repolarization exceeding the threshold of regulatory concern after repeated administration of
daily oral doses of 10 and 30 mg to healthy male and female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Actelion
Treatments:
Fluoroquinolones Macitentan Moxifloxacin Norgestimate, ethinyl estradiol drug combination